Table 1.
Base-case values and ranges used in sensitivity analyses (± 30 %)
| Parameters | Base estimate | Lower Limit- Upper Limit | Assumed distribution |
|---|---|---|---|
| Transition Probability | |||
| PFS for sorafenib | 0.1533 | 0.1073–0.1993 | Beta |
| PFS To PD for sorafenib | 0.0627 | 0.044–0.082 | Beta |
| PD To death for sorafenib | 0.1184 | 0.063–0.154 | Beta |
| PFS for SBRT | 0.086 | 0.061–0.034 | Beta |
| PFS To PD for SBRT | 0.109 | 0.076–0.142 | Beta |
| PD To death for SBRT | 0.0399 | 0.028–0.052 | Beta |
| Utility | |||
| PFS for sorafenib | 0.76 | 0.546–1.014 | Beta |
| PD for sorafenib | 0.68 | 0.476–0.806 | Beta |
| PFS for SBRT | 0.72 | 0.504–0.936 | Beta |
| PD for SBRT | 0.63 | 0.441–0.819 | Beta |
| Direct Medical Costs (US$ = 33 NT) | |||
| cPFS for sorafenib | 563365 | 394355–732375 | Constant |
| cPFS for SBRT | 259056 | 181339–336773 | Constant |
| cPD for sorafenib | 417528 | 292270–542786 | Constant |
| cPD for SBRT | 417528 | 292270–542786 | Constant |
Abbreviations: c cost, SBRT sterotactic body radiation therapy, PFS progression free survival, PD progression disease